KPV Integrative Peptides, tseem hu ua -MSH(11–13) C-terminal tripeptides, yog cov tseem ceeb ua haujlwm tawg tau muab los ntawm melanocyte-stimulating hormone -MSH. Paub txog nws "muaj zog tiv thaiv- mob, mob me me, tsis muaj- khaus, thiab tau yooj yim" cov khoom, nws tau rov ua dua tshiab hauv cov kev tshawb fawb txog kev mob thiab kev kho kab mob hauv daim tawv nqaij thiab cov mucous membranes, thiab tseem muaj nyob rau hauv qee cov tshuaj pleev xim rau kev ua haujlwm thiab daim ntawv thov kev kho mob ntawm daim tawv nqaij.
Raws li kev tshawb fawb peptide nrawm, kev thov rau cov khoom siv raw khoom tau nce siab. Shaanxi Medibridge, lub chaw tsim khoom ua ke tag nrho- cov tub lag luam nrog ntau dua 14 xyoo hauv thaj teb, muab cov khoom siab siab -purity luv peptides ntawm 99% lossis siab dua. Peb KPV, piv txwv li, tsis muaj tsawg dua 99.58% ntshiab, yooj yim tshaj li 95% + kev lag luam benchmark. Peb xa cov khoom lag luam ruaj khov, lub sijhawm ua haujlwm, thiab cov ntaub ntawv los txhawb kev txhim kho los ntawm kev ntsuas qhov ntsuas los ntawm qhov ntsuas - nce thiab ntau lawm.

COA
|
|
||
|
Khoom npe |
CAS Nr |
Batch Number |
|
KPV Peptide |
67727-97-3 |
MB2510231852 |
|
Hnub tim tsim khoom |
Hnub Soj Ntsuam |
Hnub Kawg |
|
2025-10-23 |
2025-10-24 |
2027-10-22 |
|
Qauv Qty Base |
Ntim |
Txoj Kev Xeem |
|
450.52 Nws |
10GS / lub raj mis |
HPLC |
|
Yam khoom |
Txuj |
Cov txiaj ntsig |
|
Purity |
Ntau dua lossis sib npaug li 98% |
99.56% |
|
Peptide Assay |
Ntau dua lossis sib npaug li 80% |
83.29% |
|
Loj Spectrum |
342.43 |
342.43 |
|
Solubility |
Soluble hauv dej |
Ua raws |
|
Clarity thiab xim ntawm kev daws |
Ntshiab thiab tsis muaj xim |
Ua raws |
|
Sodium ntsev |
<5.0% |
1.72% |
|
Dej |
Tsawg dua lossis sib npaug li 7.0% |
3.16% |
|
Residual Solvent: |
||
|
Methanol |
Tsawg dua lossis sib npaug li 0.3% |
Ua raws |
|
Isopropanol |
Tsawg dua los yog sib npaug li 0.5% |
Ua raws |
|
Cov tshuaj acetonitrile |
Tsawg dua lossis sib npaug li 0.041% |
0.005% |
|
Methylene Chloride |
Tsawg dua lossis sib npaug li 0.06% |
0.019% |
|
N,N{0}}Dimethylformamide |
Tsawg dua lossis sib npaug li 0.075% |
Ua raws |
|
Triethylamine |
Tsawg dua lossis sib npaug li 0.029% |
Ua raws |
|
Tert -butyl methyl ether |
Tsawg dua los yog sib npaug li 0.5% |
0.183% |
|
Endotoxin |
Tsawg dua lossis sib npaug li 0.5 EU / mg |
Ua raws |
|
Microbial txwv |
Tag nrho cov kab mob aerobic<100 CFU/g Tag nrho cov poov xab & pwm<50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Cia |
Khaws rau hauv qhov chaw tsaus thiab txias qhuav (-20 txog 8 degree) |
|
|
Xaus |
Cov batch ua raws li IN-HOUSE tus qauv |
|
|
|
||
Specification (rau kev tshawb fawb siv nkaus xwb)
Peb qhov zoo
1.KPV purity Ntau dua los yog sib npaug rau 99.58% (RP-HPLC/LC-MS), siab tshaj qhov siab tshaj lossis sib npaug rau 95% cov cai.
2.14+ xyoo, integrated manufacturing thiab QC.
3. Cov khoom sib txuam; tag nrho COA thiab MS tus kheej.
4.Scalable mov: mg rau multi-kg; luv luv sij hawm.
5.Txoj kev xaiv: N-Ac, C-Am, ntsev; aliquots.
6.Lyophilized, amber vials; txias-chain shipping; kev txhawb nqa.
|
Daim ntawv |
Qauv Order |
Specification |
|
Cov hmoov nyoos |
1 g |
Purity yog NLT 99.58% |
|
Vials |
10 vials |
3ml / 5ml / 7ml / 15ml vials thiab lwm yam. |
Kev khiav hauj lwm Mechanism ntawm KPV
Cell nkag thiab Receptor Dependence
Hauv cov kab mob epithelial xws li plab hnyuv epithelium,KPV Itsis zooPcov eptidestuaj yeem coj mus rau hauv lub cell ntawm oligopeptide transporter PepT1. Thaum PepT1 yog inhibited / poob qis, nws cov tshuaj tiv thaiv - cov nyhuv inflammatory yog qhov tsis muaj zog, qhia tias "kev nkag mus rau hauv lub cev" yog qhov tseem ceeb rau nws txoj haujlwm.
Nyob rau hauv keratinocytes thiab fibroblasts, tsis muaj kev ruaj ntseg dependence ntawm classical melanocortin axis zoo li MC1R tau pom; Txawm tias tsis muaj MC1R los yog nyob rau hauv cov xwm txheej ntawm kev ntxiv antagonists, nws tseem tuaj yeem cuam tshuam kev nyeem ntawv, qhia tias nws lub ntsiab mechanism yog receptor- ywj siab / qis- nyob ntawm.

Inhibition ntawm Inflammatory Signaling Axis
NF-κB Txoj Kev: Hauv TNF- , IL-1 , lossis LPS stimulation qauv, KPV tuaj yeem txo qis phosphorylation ntawm IKK/IκB, inhibit p65 subunit nuclear translocation, thiab tom qab ntawd txo qis ntau NF-κB hom phiaj CL-6, IL-8, TNF, PTGS2/COX-2, NOS2/iNOS). Ntawm qib protein, qhov no qhia tau tias txo qis ntawm COX-2 thiab iNOS; ntawm qib secretory, nws manifests raws li ib tug tseem ceeb txo nyob rau hauv inflammatory cytokines thiab chemokines.
MAPK Txoj Kev: Hauv ntau lub xov tooj ntawm tes, p38 thiab JNK phosphorylation qib raug txwv, thaum cov nyhuv ntawm ERK txawv nyob ntawm tus qauv. Inhibition ntawm no axis thiab NF-κB downregulation yog additive, amplifying lub zuag qhia tag nrho inhibitory nyhuv ntawm pro-inflammatory transcriptional network.
Qib tus xa xov thib ob: Cov khoom no tsis ruaj khov hauv kev txhim kho cAMP, thiab nws tsis tsim kom muaj kev txhawb nqa ntawm PKA/CREB, uas txawv ntawm hom classic ntawm -MSH ontology ntawm MC1R-cAMP-PKA, ntxiv txhawb nws "atypical melanocortin-zoo li" yam ntxwv.

Barrier Homeostasis thiab Tight Junction Protection
Nyob rau hauv tus qauv epithelial/keratinocyte monolayer, KPV nce transepithelial hluav taws xob tsis kam (TEER) thiab txo cov bypass permeability ntawm FITC-labeled probes; immunofluorescence qhia tau hais tias kev txuas ntxiv thiab kev nplua nuj ntawm ZO-1 (TJP1), Occludin (OCLN), thiab qee qhov Claudin ntawm lawv cov kev sib txuas hauv online tau khaws cia lossis rov qab los.Tawm tsam keeb kwm yav dhau los ntawm inflammatory stimulation -induced degradation thiab txav ntawm cov nqaij ntshiv ntawm cov nqaij ntshiv, KPV txo cov kev ntxhov siab thiab cytoskeletal teeb meem ntawm cov kinases txuam, yog li khaws cov membrane anchoring thiab barrier muaj nuj nqi ntawm junctional complex. Qhov kev cuam tshuam no yog kev sib koom ua ke nrog kev tiv thaiv kev tiv thaiv - inflammatory transcriptional repression.

Innate Immunity thiab Cell Interactions
Neurocytic Axis: Nyob rau hauv vivo stimulation (xws li TPA pob ntseg o, UV / tshuaj stimulation), cov khoom no txo cov kev ua ntawm myeloperoxidase (MPO) thiab neutrophil infiltration, uas ua rau txo qis hauv cov qhab nia ntawm qhov mob; Qhov no yog ua raws li nws qhov kev txo qis ntawm chemokines xws li IL-8.Macrophages/Dendritic Cells: Tawm tsam cov keeb kwm yav dhau ntawm Tus Xov Tooj -zoo li receptor activation xws li LPS, KPV inhibits qhov tso tawm ntawm TNF- thiab IL-1, txo cov kab mob paracrine; Kev hloov mus rau qhov qis-inflammatory phenotype tau pom nyob rau hauv qee cov qauv, tab sis qhov kev hloov no yog kab ntawm tes thiab microenvironment nyob ntawm.

FAQ
Q: KPV yog dab tsi?
A: KPV yog cov hluavtaws tripeptide Lys-Pro-Val (H-K-P-V-OH; MW ≈342.44 g/mol).
Q: Dab tsi yog qhov purity thiab nws paub tseeb li cas?
A: A: Peb KPV ntau dua lossis sib npaug li 99.58% ntshiab los ntawm RP-HPLC nrog LC-MS kev lees paub tus kheej thiab tag nrho COA.
Q: Nws muab thiab khaws cia li cas?
A: Lyophilized hmoov hauv amber vials; khw desiccated ntawm -20 degree, tiv thaiv los ntawm lub teeb.
Q: Kuv yuav rov ua nws li cas?
A: Dissolve hauv BAC dej los yog PBS (los yog 0.1% -1% acetic acid yog xav tau), ces aliquot thiab khov.
Q: Puas yog nws tsis muaj menyuam thiab ua li cas txog endotoxin?
A: Kev tshawb fawb-siv nkaus xwb; tsis yog sterile tshwj tsis yog hais kom tsis muaj menyuam-filtered, nrog rau kev kuaj endotoxin muaj nyob ntawm kev thov.
Q: Koj puas muab cov kev cai tshwj xeeb lossis kev ntsuas ntsuas?
A: Yog-N-acetylation, C-amidation, ntsev cov ntaub ntawv, aliquoting, thiab ntau lawm los ntawm mg rau ntau-kg.
Q: Yuav ua li cas yog nws shipping?
A: ruaj khov rau kev thauj mus los niaj hnub; khov ntawm daim ntawv txais nyiaj.
Q: Puas yog Shaanxi Medibridge lub chaw tsim khoom ntawm peptides rau kev tshawb fawb?
A: Yog lawm, peb yog cov chaw tsim khoom ua ke tag nrho- cov tub lag luam nrog ntau tshaj 14 xyoo hauv thaj teb.
Shaanxi Medibridge yog lub chaw tsim tshuaj paus peptide ua haujlwm rau cov tsev kawm ntawv qib siab thiab cov chaw kuaj mob thoob ntiaj teb. Peb muab lyophilizedKPV Integrative Peptidesrau kev tshawb fawb siv, lav purity Ntau dua los yog sib npaug rau 99.72%. Cia siab tias lub sijhawm ua cov khoom lag luam txhim khu kev qha, ua tib zoo ntim, kev txhawb nqa sai, thiab muaj cov khoom muaj nyob hauv cov khoom sib xws. Kev xa khoom thoob ntiaj teb. Rau cov lus hais lossis cov qauv: hi@medibridgeapi.com lossis WhatsApp +44 07548632075.
Cim npe nrov: Tuam Tshoj kpv integrative peptides manufacturers, lwm tus neeg, Hoobkas



